Sparrow Pharmaceuticals, a targeted cardiometabolic therapeutics company, today announced the appointment of George Eldridge as Chief Financial Officer. Mr. Eldridge brings more than two decades of biotechnology financial leadership, including experience guiding multiple companies through successful initial public offerings.
